drugset / Trial / NCT03491371
Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
Completed
56 enrolled
Peking University People's Hospital
Peking University International Hospital · collabPeking University Shougang Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of three Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated sarcoma.
Timeline
- Start
- 2015-06-01
- Primary completion
- 2016-12-31
- Completion
- 2017-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | — | — |